{"DataElement":{"publicId":"7307664","version":"1","preferredName":"NCCN Cytogenetic Risk Group for ALL Initial Diagnosis Category","preferredDefinition":"A description of the NCCN cytogenetic risk group for ALL initial diagnosis.","longName":"NCCN_CYTO_RSK_GP_ALL_DX_CAT","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"7307658","version":"1","preferredName":"NCCN Cytogenetic Risk Group for ALL Initial Diagnosis","preferredDefinition":"A classification strategy for Acute Lymphoblastic Leukemia (ALL) developed by NCCN that stratifies risk groups based on the cytogenetic and molecular features of ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020):The first diagnosis of the individual's condition.","longName":"7307655v1.00:7307656v1.00","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"7307655","version":"1","preferredName":"NCCN Cytogenetic Risk Group for ALL","preferredDefinition":"A classification strategy for Acute Lymphoblastic Leukemia (ALL) developed by NCCN that stratifies risk groups based on the cytogenetic and molecular features of ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","longName":"C172166","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Cytogenetic Risk Group for ALL","conceptCode":"C172166","definition":"A classification strategy for Acute Lymphoblastic Leukemia (ALL) developed by NCCN that stratifies risk groups based on the cytogenetic and molecular features of ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A0D82F-24CE-713A-E053-4EBD850A850D","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7307656","version":"1","preferredName":"Initial Diagnosis","preferredDefinition":"No Value Exists","longName":"C156813","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Initial Diagnosis","conceptCode":"C156813","definition":"The first diagnosis of the individual's condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A0D82F-24DE-713A-E053-4EBD850A850D","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A0D82F-24EE-713A-E053-4EBD850A850D","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"KUMMEROA","dateModified":"2023-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7307661","version":"1","preferredName":"NCCN Cytogenetic Risk Group for ALL Category","preferredDefinition":"A classification strategy for Acute Lymphoblastic Leukemia (ALL) developed by NCCN that stratifies risk groups based on the cytogenetic and molecular features of ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)_A grouping of items based on some commonality or by user defined characteristics.","longName":"NCCN_CYTO_RSK_GP_ALL_CAT","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Poor Risk","valueDescription":"NCCN Cytogenetic Risk Group for ALL, Poor Risk","ValueMeaning":{"publicId":"7307662","version":"1","preferredName":"NCCN Cytogenetic Risk Group for ALL, Poor Risk","longName":"7307662","preferredDefinition":"ALL characterized by hypoploidy (less than 44 chromosomes, KMT2A rearranged (t[4;11] or others), t(v;14q32)IgH, t(9;22)(q34;11.2): BCR-ABL1 (defined as high risk in the pre-TKI era), complex karyotype (5 or more chromosomal abnormalities), Ph-like ALL; intrachromosomal amplification of chromosome 21 (iAMP21). (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Cytogenetic Risk Group for ALL, Poor Risk","conceptCode":"C172168","definition":"ALL characterized by hypoploidy (less than 44 chromosomes, KMT2A rearranged (t[4;11] or others), t(v;14q32)IgH, t(9;22)(q34;11.2): BCR-ABL1 (defined as high risk in the pre-TKI era), complex karyotype (5 or more chromosomal abnormalities), Ph-like ALL; intrachromosomal amplification of chromosome 21 (iAMP21). (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A20682-4173-7B29-E053-4EBD850A4276","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A20682-418C-7B29-E053-4EBD850A4276","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"},{"value":"Good Risk","valueDescription":"NCCN Cytogenetic Risk Group for ALL, Good Risk","ValueMeaning":{"publicId":"7307663","version":"1","preferredName":"NCCN Cytogenetic Risk Group for ALL, Good Risk","longName":"7307663","preferredDefinition":"ALL characterized by hyperploidy (51-65 chromosomes or t(122;21)(p13;q22): ETV6-RUNX1. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Cytogenetic Risk Group for ALL, Good Risk","conceptCode":"C172167","definition":"ALL characterized by hyperploidy (51-65 chromosomes or t(122;21)(p13;q22): ETV6-RUNX1. (Adapted from NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A20682-4198-7B29-E053-4EBD850A4276","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6A20682-41B1-7B29-E053-4EBD850A4276","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7307660","version":"1","preferredName":"NCCN Cytogenetic Risk Group for ALL Category","preferredDefinition":"A classification strategy for Acute Lymphoblastic Leukemia (ALL) developed by NCCN that stratifies risk groups based on the cytogenetic and molecular features of ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020):A grouping of items based on some commonality or by user defined characteristics.","longName":"C172166:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Cytogenetic Risk Group for ALL","conceptCode":"C172166","definition":"A classification strategy for Acute Lymphoblastic Leukemia (ALL) developed by NCCN that stratifies risk groups based on the cytogenetic and molecular features of ALL. (NCCN Guidelines, Version 1.2020, February 20, 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A20682-414B-7B29-E053-4EBD850A4276","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"ONEDATA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A20682-415C-7B29-E053-4EBD850A4276","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"KUMMEROA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"B-ALL Cytogenetics Risk Group","type":"Preferred Question Text","description":"B-ALL Cytogenetics Risk Group Initial Diagnosis Type","url":null,"context":"DCI"}],"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6A05823-C138-2379-E053-4EBD850A4FE1","latestVersionIndicator":"Yes","beginDate":"2020-05-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-27","modifiedBy":"KUMMEROA","dateModified":"2020-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}